PROFILE at 5 Years: Treating Crohn’s Early: The Lancet Gastroenterology & Hepatology | September 2026
What Did the Study Find?
PROFILE followed newly diagnosed Crohn’s disease patients originally randomized to top-down infliximab + immunomodulator or conventional step-up therapy.
At ~5 years, Crohn’s-related surgery occurred in 6 top-down vs 26 step-up patients.
Step-up therapy carried a >5-fold higher hazard of surgery.
Hospitalization was lower with top-down treatment: 11% vs 21%.
Progression to stricturing or penetrating disease occurred in 7% vs 17%.
Importantly, 89% of step-up patients eventually received biologic or immunomodulator therapy, yet did not catch up.
Serious infections and malignancies were similar between strategies.
Why Does It Matter?
These findings suggest a genuine early therapeutic window in Crohn’s disease: delaying effective treatment—even by months—may permit irreversible bowel damage.
GastroAGI Takeaway
This strengthens the case for disease modification through early advanced therapy. For newly diagnosed moderate-to-severe Crohn’s disease, waiting for conventional step-up failure may no longer be the optimal strategy. Early effective therapy can potentially prevent hospitalization, structural complications and surgery—not simply control symptoms.
